Augustine Therapeutics: Funding, Investors & Team (Sep 2026)
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations of selective HDAC6 inhibitors that can be used to treat axonopathies like Charcot Marie Tooth disease. These new compounds show promise in protecting against nerve degeneration and aiding in the repair of peripheral myelin and axons.
Augustine Therapeutics has raised $102M across 2 funding rounds on record, the most recent a Series A of $84.1M announced in Mar 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Augustine Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2025.
Augustine Therapeutics Funding Rounds
Augustine Therapeutics raised $18.2M in a Series A announced in Jun 2024.
9 months later, a Series A of $84.1M was announced in Mar 2025.
Augustine Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Augustine Therapeutics Funding Compared to Other Biotechnology Startups
Augustine Therapeutics' latest round of $84.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Augustine Therapeutics in Biotechnology and Leuven
Companies Similar to Augustine Therapeutics
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
Augustine Therapeutics Funding FAQs
What does Augustine Therapeutics do?
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations of selective HDAC6 inhibitors that can be used to treat axonopathies like Charcot Marie Tooth disease. These new compounds show promise in protecting against nerve degeneration and aiding in the repair of peripheral myelin and axons.
How much funding has Augustine Therapeutics raised?
Augustine Therapeutics has raised $102M across 2 rounds on record. The most recent is a Series A of $84.1M announced in Mar 2025.
When did Augustine Therapeutics last raise funding?
Augustine Therapeutics' most recent funding round on record is a Series A of $84.1M, announced in Mar 2025.
Who founded Augustine Therapeutics?
FundedIQ lists Joris De Wit (Founder) at Augustine Therapeutics.
Where is Augustine Therapeutics headquartered?
Augustine Therapeutics is based in Leuven, Vlaams-Brabant, Belgium.
How many employees does Augustine Therapeutics have?
Augustine Therapeutics is in the 11-50 employee band.
How does Augustine Therapeutics' funding compare to other Biotechnology startups?
Augustine Therapeutics' latest round of $84.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Augustine Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Augustine Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.